Dahua Jixian analysts Carol Dou and Sunny Chen report that BeiGene can achieve sustainable revenue growth by launching new products. They believe the company's new revenue target of $5.1 billion to $5.3 billion is likely to be met, and they expect to use its global operating platform to further improve operational efficiency and cash generation capabilities. Analysts at Dahua Jixian said that BeiGene's anti-cancer treatment Brukinsa is likely to continue to boost global sales in the next few years, thanks to its best-in-class characteristics and growing market penetration rate. They said, “BeiGene has entered a new era of development and will achieve positive profits and positive free cash flow from 2025. “The reason, they say, is a more diversified revenue structure and increasing profit margins. Dahua Jixian rated the stock as a buy, with a target price of HK$252.00.

Dahua Jixian analysts Carol Dou and Sunny Chen report that BeiGene can achieve sustainable revenue growth by launching new products. They believe the company's new revenue target of $5.1 billion to $5.3 billion is likely to be met, and they expect to use its global operating platform to further improve operational efficiency and cash generation capabilities. Analysts at Dahua Jixian said that BeiGene's anti-cancer treatment Brukinsa is likely to continue to boost global sales in the next few years, thanks to its best-in-class characteristics and growing market penetration rate. They said, “BeiGene has entered a new era of development and will achieve positive profits and positive free cash flow from 2025. “The reason, they say, is a more diversified revenue structure and increasing profit margins. Dahua Jixian rated the stock as a buy, with a target price of HK$252.00.